~~<i id='2A38A668A0'><strike id='2A38A668A0'><tt id='2A38A668A0'><pre id='2A38A668A0'></pre></tt></strike></i>~~

Home» focus» fashion

fashion

author：focus 2025-09-04 14:15:05 Page View：6413

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Judges halt a Biden rule offering student debt relief for those alleging colleges misled them
Next article： How to save PrEP access — and even expand it

comprehensive

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

The leaders of Italy and Poland say European Union should focus on stopping migration

Poland'sPrimeMinisterMateuszMorawiecki,right,andItaly'sPrimeMinisterGiorgiaMelonispeakduringanewscon

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

2:59PoliceofficersworkatthesceneasinvestigationsareongoingthedayafteramassshootingintheKingsessingse

WSS

fashion

fashion

explore

comprehensive

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder